Clever Leaves Holdings Inc (CLVR)

[diduknow]

Peace out bro, he who gets out first here, gets out best. Sell shares to that guy Tim Seymour and you will be good to go. I am waiting for Hindenburg event.

[kahlua]

This board has been overrun by a blind bull and a blind bear.
I’ll let you two senselessly make your paper thin cases as to why you know it all.
Peace out!

[diduknow]

I expect 7-10 dollar range til markets open up. Regulation matters, not cost per gram if you can sell it in volume, and CBD is a dime a dozen with prices dropping quickly in an oversupplied USA. Where are their sku's selling here? I cannot find em anywhere anymore.

[misteroldman]

BIG WEEK AHEAD. Great work to those who bought the dip last week. this week we get outta the $10 range and back up to $12

[misteroldman]

DIDUKNOW YOU dont know anything? LOL you are clearly a moron

[misteroldman]

LOL you all need to chill. trying to predict this market is a joke and any pro knows it. Clearly NONE of you are retired pros and clearly retail. That is fine but you should all understand something. WHEN IT COMES TO A NEW INDUSTRY BEING BORN... YOU CANNOT GO OFF NORMAL TRADING PATTERNS AND FUNDAMENTALS. Therefore you all are very very wrong and will never predict this play. Projections mean nothing and this company will pivot and move before your predictions can come into play. THIS COMPANY WILL BE FINE and you WILL see the SP over $20 once things settle out in the industry. You all are immature impatient investors who think if it doesnt move up 20-100% in the first few weeks you buy the stock then it must a terrible stock .LMAO. you are all idiots, all you millenial and gen z robinhood morons. I only check these boards and post on them for my own entertainment. SO MANY NEWBIE MORONS TRYING T TRADE THESE PAST 2-3 years. LOL Well, if NAY of you THINK you can predict a cannabis stock, you are very very GREEN. NOTHING MATTERS, ANY POT PLAY WILL SKY ROCKET WITH THE RIGHT NEWS AND LEGALIZATION. CLVR WILL BE THE #1 COMPANY IN THE WORLD becuase the PRODUCE THE #1 Product and the CHEAPEST PRICE. EVEN CGC IS USING THE TO FILL THEIR NEEDS BECAUSE THEY PRODUCE SUCH HIGH QUALITY CANNABIS AT SUCH A LOW PRICE

[kahlua]

The 2021 revenue outlook reduction was without a doubt a slap in the face to any investor closely following this company. The burn rate will be significantly higher this year than initially projected. Yes they will probably exit 2021 with barely $40M cash. Very disappointing developments without a doubt. But again your smarmy mocking tone is absolutely not useful except to perhaps bolster your ego.

I expect the stock to remain range bound between 9 to 14, awaiting a significant catalyst. Take or pay announcements won’t cut it unless they are very significant. Better visibility in the 2H would also possibly catalyze the stock. Decriminalization is the big behemoth outlier event. All imo

[misteroldman]

CLEVER COST TO PRODUCE CANNABIS is 90% CHEAPER THAN COMPETITORS. This is the commercial play and the company that will come out on top! JMHO. Elevation levels at grow site keep pest control costs down NATURALLY and location on earth gives constant 12 hour sunlight 12 hour darkness. (unlike other parts of the world where companies have to trick the plant into this and trick the plant into the temperature year round and the heating bills are astronomical. Also, lets not forget CLVR is one of the few certified companies to be doing business in columbia and peru.

US MARKET: once NASDAQ removes barriers or USA decriminalizes and at the least make medical legal federally, CLV R is positioned extremely well with USA distribution channels and will be ready to supply and FLOOD the market with HIGH QUALITY CANNABIS FLOWER AND EXTRACTS at a COST cheaper than competitors and higher profit margins than competitors.

CGC already acknowledged CLVR as the cheaper option and has begun to create business agreements with CLVR. Look it up do you own DD. ETF THCX also recently acknowledges CLVR as a disruptive force in this industry and has started adding the stock to the ETF last February 2021. THIS IS HUGE and other ETFs will follow if they havent already. Being a SPAC this company has been hit hard by SHORT PRESSURE. Squeeze coming imo.

[diduknow]

Please buy as they halved their outlook, are gonna burn thru cash this yr and have to fluff pr potential CBD sales. C'mon kids buybuybuy.

[misteroldman]

BIG BUYS on the NEWS!!!! Looking good. Should see $14 soon at this pace! Once this break $11 this will fly again. CRAZY it got this low ONLY SHORTS caused that

[misteroldman]

NEW YORK, April 01, 2021 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR) (“Clever Leaves” or the “Company”), a leading multi-national operator and licensed producer of pharmaceutical-grade cannabinoids, today announced an agreement with Verdemed Holdings Inc. (“Verdemed”), a Latin American pharmaceutical cannabis company based in Toronto, Canada, to supply finished CBD products for the Brazilian and Peruvian markets. The initial portfolio of products includes finished formulations of CBD oral solutions with different concentrations used for different indications.

Verdemed supplies cannabis products in Brazil under the compassionate use model and has submitted applications to register finished products in Brazil and Peru. The products manufactured under this partnership will be registered as pharmaceutical products and sold into distribution channels such as pharmacies and drugstores.

“Verdemed is an important player in the Brazilian market with existing access to patients and is well-positioned to tackle the high regulatory hurdles in Brazil and Peru. This partnership expands Clever Leaves’ presence in one of the largest markets in South America,” said Kyle Detwiler, CEO of Clever Leaves. “We are committed to increasing access for the millions of patients within the growing Brazilian and Peruvian markets, and they will soon have access to the high-quality products we produce thanks to Verdemed’s network.”

“Partnering with Clever Leaves aligns with Verdemed’s mission to offer the best cannabinoid products to all Latin Americans,” said José Bacellar, CEO of Verdemed. “Clever Leaves’ products meet all of the regulatory and product quality standards in each of our key markets, and their EU GMP and INVIMA GMP certifications distinguish their products and bring higher value to patients.”

The Brazilian and Peruvian markets are expanding, and it is estimated that the Brazilian medical cannabis user base could reach close to 3 million people in the next few years. According to Prohibition Partners, with a population of 32 million, Peru’s medical cannabis market is estimated to be worth approximately $100 million. As of September 2020, almost 8,000 patients were registered in the DIGEMID, Peru’s drug regulatory authority database.

About Verdemed Holdings Inc.
Verdemed brings affordable cannabinoid-based pharmaceuticals to doctors and patients in Latin America, in all countries, in all jurisdictions legally authorized to sell medical cannabis. The company’s initial focus is on product formulations of cannabinoid pharmaceuticals currently available in Canada, Europe, and the USA.

Verdemed established a wholly-owned, active-controlled substances pharmaceutical import laboratories in Brazil and Peru, which are registered in compliance with Anvisa and DIGEMID for cannabis-derived products. Its goal is to scale-up exclusive strategic supply chain partnerships with GMP-certified API providers for the industrial production of pharmaceutical grade CBD oil formulations.

About Clever Leaves Holdings Inc.

Clever Leaves is a multi-national cannabis company with an emphasis on ecologically sustainable, large-scale cultivation and pharmaceutical-grade processing as the cornerstones of its global cannabis business. With operations and investments in the United States, Canada, Colombia, Germany and Portugal, Clever Leaves has created an effective distribution network and global footprint, with a foundation built upon capital efficiency and rapid growth. Clever Leaves aims to be one of the industry’s leading global cannabis companies recognized for its principles, people, and performance while fostering a healthier global community. Clever Leaves has received multiple international certifications that have enabled it to increase its export and sales capacity from its Colombian operations, including European Union Good Manufacturing Practices (EU GMP) Certification, a Good Manufacturing Practices (GMP) Certification by Colombia National Food and Drug Surveillance Institute - INVIMA, and Good Agricultural and Collecting Practices (GACP) Certification. Clever Leaves was granted a license in Portugal from Infarmed – the Portuguese health authority – which allows Clever Leaves to cultivate, import and export dry flower for medicinal and research purposes. In addition, the Portuguese operation was granted certification of compliance with GACP and IMC-GAP.

[kahlua]

[diduknow]

3 customers are 74% of receivables and GNC, the biggest, went bankrupt? CBD sales are a dime a dozen anyway.

[diduknow]

The local drug dealer down there sells more in a quarter and does not bleed cash. Hang in there and you are Khiron or Pharmacielo over time.

[kahlua]

Put up or shut up. Offer due diligence and fundamental or technical analysis or please move on.

[diduknow]

This is a lemming. $5.00 by fall.

[kahlua]

Well if many others market participants made 1000% last year like you did then we may be much closer to the end of the 1999 scenario. The only time I saw such returns was in 99 before the equity bubble burst in March 2000. I certainly see anecdotal evidence everywhere of speculators being rewarded far more than fundamentals would normally allow. Certainly Understand your capital preservation stance. I gave a lot of my gains back in 2000 near market due to complete lack of valuation analysis. Although frankly if I’d have had any of that understanding I probably would never have bought the stocks in my portfolio, many of which went parabolic! Lol

The momentum got wrung out of the mj sector super fast recently . But as long as the overalll market doesn’t fall apart I’d expect 2H 21 to potentially offer upward momentum on removal of 280E and perhaps the beginnings of a decriminalization framework coming together. Big tobacco and alcohol are part of the group pushing hard to get the Federal government on the same page as the states. Also they want this wrapped up and in place way before the mid term run up so I’m thinking they hash out their differences and get decrim done prior to YE so it can roll out in 22.

Frankly there are so many scenarios that support an upward trajectory for CLVR but the biggest in the medium term, would be US decrim. The market unraveling due to unchecked sky rocketing yields is probably the biggest threat that I can see. All imo

[Freeparking100]

We see things similarly. I was of the same macro thesis. The fact everyone sees it the same signals me a bad feeling. After all its the market movers that determine stock movements not the macro. Just my conspiracy theory Maybe. The people who run the markets run the White House. They have for decades. I don’t believe either side represents Americans best interest but corporate interests. We live in a corporate socialist society blah blah blah I could go on.

Chinese bonds are seeing increased interest as they are more attractive for international investment. The fed has signaled they are going to let yields rise as long as there is liquidity. 2+2. Literally day after Biden’s speech bonds started pushing strong again I watched 10 yr futures all day i might get in big Monday.

I’m up 1000% since beginning of last year. I have to protect my assets now. Still small but substantial options positions to reap a big reward if we see the macro picture play out.

[kahlua]

Kyles point about how they’re positioning themselves in regards to German distribution is way ahead of the curve and I’d expect them to continue to employ that distribution moat strategy. I expect any M&A they do to be focused on the distribution side. Its very possible Kyle is positioning this company for a possible pharma buyout in a few years time.

https://www.valuewalk.com/curaleaf-deal-future-cannabis-market-europe/

[kahlua]

What about Biden spooked you? Frankly almost every politician is in the back pocket of business and special interests, with just a wink and a nod to s alight platform differential between right and left - they all serve money regardless of what side of the aisle they sit on or the rhetoric that spews from their mouths. Just my opinion.

I’m concerned with the changing macro trends especially the 10 year. The EU has come out aggressively saying they will control the long end of their yield curve to keep interest costs low and its probable our Fed may do the same if our 10 year yield gets much higher. If that happens I expect a full on buying binge in commodities, precious metals and equities as the USD gets pummeled. Equities may run toward a parabolic blow off top. Sheer conjecture at this point but a lot of solid Elliot wave technicians seem to be pointing to that possibility just based on equity index chart setups.

In terms of CLVR if an equity bear market ensues the stock could easily get cut in half because the current valuation premise is based on a projection model yet to be proven out but if the market indeed goes into blow off mode then CLVR could go on very a big run, especially if they begin to prove out the aggressive growth projections, with the caveat being to get out before the music stops. I remember what happened to equities in 2000 and it was absolutely brutal. All imo

[Freeparking100]

Yeah biden spooked me. Got out most of my positions and holding cash this am. Might be a shakeout. It worked on me

[kahlua]

IR confirmed Q4 will be released near end of March but aside from adding in the additional Greencare up front 2M prepayment, I don’t expect the rest of the results to be much better than Q3, so I’d imagine we’re looking at a 6M quarterly loss, which should be baked into the share price. What is a bit more significant is that aside from the announcement about clvr importing CBD topicals for their herbal brand company, to distribute, which Kyle has stated is in very early goings at this juncture, CLVR has not reported any additional sales contracts in 2 months (Entourage phytolab was announced Jan 12). My hope is they are partnering with companies who prefer to keep a low profile but without contract news there’s really no way to gauge their success until quarterlies are announced.

[kahlua]

Warrants are also in am ascending triangle pattern but they were held down going into the close and did not break to the upside like the commons. With sector and Nasdaq weakness this morning we will have to see if the shorts and general sector weakness leads to invalidating yet another breakout pattern and further weakness ensues. All imo

[kahlua]

I forgot about THCX. Per website they hold about 352k shares so not a significant portion of the estimated float.
https://thcxetf.com/fund/thcx-holdings/

The daily short ratio has backed off a bit down to 20% the last few days. I’d be really curious for an accurate amount of current shorts outstanding. The stock broke an ascending triangle yesterday targeting 15 but with the pre market looking awful, shorts may pile back on and invalidate yet another chart breakout. As I said, it’s looking like the shorts are piling on for a sector washout.

For such a low float stock the volume is actually very liquid and even though lately you can clearly see the trade volume has backed off from the daily average as momentum buyers have rotated out or taken the short side, the stock still trades just under a million shares, which is excellent. The Mexico news should have lit a fire under CLVR as it did Khiron, which is up 100% in a week or so. Truly ironic to see a Nasdaq listed stock be more manipulated than a Canadian venture stock!

[Freeparking100]

Shorts covering here. Warrants just got slapped and options ask rose 20%. Time for momo up

[Freeparking100]

Are you including thcx shares bought up? It’s pretty clear they were the buyer at 18ish. That was 8M est. gap up. I’m not sure how that calculates to float but might explain only 1.5M float. Fintel definitely doesn’t always have most up to date info. Either way if any decent size buyer shows up they need to drive this price up 4$ to get in with any size. The illiquidity speaks to an incredibly tight float.

[kahlua]

In terms of the float, recently Kyle stated in an interview it was around 8.3M prior to the PIPE lockup expiry. PIPE was around 1M shares so my estimate is a current float around 9.3M. I believe fintel has that detail wrong. I had a look at a few other sector leaders and the short volume ratio is almost identical to CLVR in the 25 to 30% range, so this clearly is a sector bet.

Yields on the 10 year have backed off but clearly macro trends are in major flux going forward with this 1.9T sloshing around. CLVR is completely wedded to the sector along with whether the growth/mo-mo trade is in risk on or risk off status. Hopefully CLVR starts to deliver big contract announcements and separate itself from the pack but until then the shorts will continue selling into every rally frustrating the longs in a big way. Best case scenario is the recent 10 support test holds and slowly the stock is able to climb higher and clear the many resistance zones on the chart with some positive NRs and perhaps this Mexico legalization news helps as well.

[Freeparking100]

I view it similarly. But not sure how inaccurate the float is given the institutional positions holding. 88% held according to fintel which leaves 1.5-2M maybe? but agree I thought float was 10x higher. Bond auction today is either going to switch market sentiment to buy or crater us back to recent 3700 and clvr to .09. I think bonds stay stable so betting we go up. Mexico legalization hasn’t shown up on people’s radars yet. Khiron running means Clvr will run just gotta be patient.

[kahlua]

I am certain that fintel data is not accurate. I just rechecked my notes from prior presentations and the current float after the PIPE share Lockup expiry is near 9.3M shares, so 2M shares short is about 21% of the current float although if they continue building up at 30% of average daily volume (currently 1.4M shs) they would add around 6.7M more by the end of the month, to a total of 8.7M shs. So, that being said, I do not expect the same aggressive shorting to continue unabated. My guess is this is a short momentum play based solely on the current yield curve increase slamming the nasdaq and growth/momentum plays. I would think they will look to cover in the 9 to 10 support range and frankly without a significant news release to funnel in new buyers, unfortunately,I’d imagine the shorts may win. What is even more frustrating about this is that Mexico legalization is imminent and yet the top tier Latam leader, which I believe is CLVR, is not even catching a strong bid. Hell even Khiron is up 50% in the last week due to Mexico news. Remarkable how big a factor the shorts really are at suppressing the share price at least in the short term. All imo

[Freeparking100]

Famed citadel of gme fame is currently holding 6x calls to puts. Lots of notable funds are holding massive positions. Farallon holding 2M+

[Freeparking100]

I think the recent gamma squeezes such as gme is orchestrated. I think Clvr is a good target for this manipulation

[Freeparking100]

Fintel list float as 1.5M. Lists it is held 88% insiders and institutions. Currently 166% of float, 2 days to cover based on volume. About 2M shares short. 30% short yesterday

[kahlua]

Yeah the short volume is ranging close to 30% almost everyday in March...do you have a screenshot for the short volume as % of float? That information on fintel is available only to subscribers. 150% of float would be close to 13 or 14M shares short I believe which is hard to believe and would be a very troubling statistic (institutional money is rarely wrong). The put/call ratio of .22 is far more bullish vs the reported short position.

[misteroldman]

this company going to be a major player imo

[Freeparking100]

Short interest 20%. 150% of float according to fintel. Borrow rate at 40%. Trading like they don’t want people to know they need to cover. Get ready for a rip.

[Freeparking100]

I’ve got an institutional position built on this dip. I’ll sell the actual stutes some at 50.

[kahlua]

Developments continue to just get better and better for this company...
This pending legislation, if it becomes law, would immediately change the revenue and earning potential for this company. Even near term projections would need to be modified higher.

#BREAKING New draft #cannabis legislation published by the Colombian government this week will allow for flower exports following requests from domestic producers, opening the door for exports to Europe and neighboring markets. https://t.co/DbfUVgo3FD pic.twitter.com/J8Vu9SNOXL

— Prohibition Partners (@prohibition_p) February 21, 2021

[kahlua]

There’s a chance the gap down around 12.90s fills. Despite strength on Friday both the RSI and MFI did not confirm the move which suggests a short term divergence. Just a short term view here. I’m very long this company but like to view trade setups from all angles. All FWIW.

[Freeparking100]

Hope you got some.

[Freeparking100]

Buy this dip. Weedstocks and spacs are being pressured by institutions to reduce marginability of assets to shakeout overleveraged retail. Institutions are buying here.

[kahlua]

One minor correction...there are currently around 25M shares outstanding with about 2.5M additional earn out shares available upon share price milestones being met (also completely excluding the warrants). The current float only consists of the original SAMA shareholders who were not subject to a lockup, which is around 33% of O/S, or roughly 8.25M shares. PIPE investors shares lockup expires at 45 days post despac. All this info is from investor presentation online and the recent ceo presentation , link available on company Twitter feed.

[trickledownfacists]

$80M cash
$25M share float
$.13 per gram production costs.
Operates worldwide

[kahlua]

That’s not manipulation. That’s just another big block sale overwhelming buyer demand. It has been ongoing since despac day. Company needs to generate sales and prove out the model and then buying should overwhelm sellers. All imo.

[trickledownfacists]

Heavy manipulation.

[trickledownfacists]

Added. $1B Market cap easy

[kahlua]

Yes they are worth the due diligence. Big operation in Columbia and growing a nice sized operation in Portugal along with a very strategic focus on the internationally legal medicinal B2B market (which obviously excludes US). Capital is currently blind to CLVR as it floods into the US MSO’s. Once substantive sales contracts are inked CLVR should pull out of these current low valuation doldrums imo.

[OldJames]

Just stumbled upon this company on Twitter tonight. Sent it to a buddy of mine who loves pot stocks. Their operation looks pretty decently sized

[kahlua]

Currently under the radar but worthy of several hours of due diligence to understand this team, the investment backing and the assets they have on hand and are building out. The global B2B supply chain in this industry is being re-mapped and extremely low cost high grade product from Columbia is going to be an important part of the big picture. Clever Leaves at a sub 200M EV is a bargain for investors with an eye down field. All imo

[Nocateed]

buy em when they are down, loads of cash, 4 letter stock that the robin hoodies may pile into after Georgia election, low float, perfect storm to go up, up, up!

[JohnCM]

CLVR Stock: 12 Things to Know as Cannabis Play Clever Leaves Starts Trading

After trading via a blank-check company, Clever Leaves is making its Nasdaq debut today

By Sarah Smith,
InvestorPlace
Dec 18, 2020

The Nasdaq Exchange is looking a bit green today. Why? Well, after months of trading through a special purpose acquisition company, Clever Leaves is coming public. Starting today, the cannabis play will be trading on the Nasdaq under the ticker CLVR.

So what do you need to know about CLVR stock now? And why does this SPAC merger news matter?

To start, investors should be familiar with the basics of the story. Essentially, Clever Leaves has been trading through Schultze Special Purpose Acquisition (NASDAQ:SAMA). After shareholders took a favorable vote on the SPAC merger, Clever Leaves is making its debut.

With that in mind, here are 12 things to know about CLVR stock and the Clever Leaves SPAC merger:

Schultze Special Purpose Acquisition first came public in December 2018 under the leadership of distressed debt investor George Schultze.
Since then, the blank-check company has been largely flying under the radar.

However, it announced the Clever Leaves SPAC merger in July 2020.
At the time, the two companies announced that the post-merger business would have an enterprise value near $255 million.

Now, as CLVR stock debuts, Clever Leaves will have $80 million of cash on its balance sheet.

Importantly, Clever Leaves focuses on the medical and recreational cannabis markets.

It currently operates in Colombia, Portugal, the United States, Canada and Germany.

Across those operations, it has 1.9 million square feet of greenhouses.
Additionally, Clever Leaves exports its medical-use cannabis to 14 different countries.

Beyond its cannabis brands, Clever Leaves also works on developing unique strains of cannabis, as well as cannabis research and development.

The company says its focus is on ecologically sustainable and large-scale cultivation.

Investors should also note that the company emphasizes its compliance with federal and state laws.

So why does this really matter? And why should investors pay attention to CLVR stock?

Well, investors likely know that times have been tough for cannabis businesses. Especially since the start of the novel coronavirus pandemic, some of the leading Canadian firms have really struggled. This comes as companies sort out supply-demand imbalances and also combat black-market suppliers. Plus, legalization in the U.S. at the federal level is still in the works. On that backdrop, we have seen things starting to really shakeup in the industry. Earlier this week, Tilray (NASDAQ:TLRY) and Aphria (NASDAQ:APHA) announced a huge, new merger.

Now, Clever Leaves wants to come public, relying on its SPAC merger to help it expand and grow its business. Additionally, as the company distributes non-cannabis products through one of its consumer brands, it believes that it has good access to the U.S. while it waits for federal legalization. And that is exactly where any intrigue in CLVR stock comes from.

Remember, the cannabis landscape looks to be rapidly changing. President-elect Joe Biden has promised to federally decriminalize marijuana. The House of Representatives just passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act. Plus, on Election Day, several more states decriminalized or legalized recreational cannabis use. With more set to do the same in 2021, CLVR stock maybe picking the perfect time to start trading.

As with anything in Washington, it is impossible to predict the future. However, given the timing of the SPAC merger news, investors should keep Clever Leaves and CLVR stock on their radar.